Alarm as FDA fast-tracks first antipsychotic for dementia agitation
Investigation raises serious questions about the harm-benefit balance of Rexulti Decision may reverse efforts to reduce use of antipsychotics in US care homes In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration ...

